- Home
- SFWL vs TNXP Comparison
SFWL vs TNXP Comparison
Compare SFWL & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFWL
- TNXP
- Stock Information
- Founded
- SFWL 2001
- TNXP 2007
- Country
- SFWL China
- TNXP United States
- Employees
- SFWL N/A
- TNXP N/A
- Industry
- SFWL Trucking Freight/Courier Services
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- SFWL Industrials
- TNXP Health Care
- Exchange
- SFWL Nasdaq
- TNXP Nasdaq
- Market Cap
- SFWL 80.8M
- TNXP 71.6M
- IPO Year
- SFWL 2023
- TNXP N/A
- Fundamental
- Price
- SFWL $1.00
- TNXP $9.17
- Analyst Decision
- SFWL
- TNXP Strong Buy
- Analyst Count
- SFWL 0
- TNXP 2
- Target Price
- SFWL N/A
- TNXP $5,350.00
- AVG Volume (30 Days)
- SFWL 21.1K
- TNXP 1.8M
- Earning Date
- SFWL 03-27-2025
- TNXP 03-31-2025
- Dividend Yield
- SFWL N/A
- TNXP N/A
- EPS Growth
- SFWL N/A
- TNXP N/A
- EPS
- SFWL 0.11
- TNXP N/A
- Revenue
- SFWL $446,281,000.00
- TNXP $11,291,000.00
- Revenue This Year
- SFWL N/A
- TNXP $64.71
- Revenue Next Year
- SFWL N/A
- TNXP $24.49
- P/E Ratio
- SFWL $9.29
- TNXP N/A
- Revenue Growth
- SFWL 14.80
- TNXP 183.05
- 52 Week Low
- SFWL $0.81
- TNXP $9.03
- 52 Week High
- SFWL $2.23
- TNXP $1,248.00
- Technical
- Relative Strength Index (RSI)
- SFWL 44.19
- TNXP 33.86
- Support Level
- SFWL $0.98
- TNXP $11.18
- Resistance Level
- SFWL $1.04
- TNXP $12.42
- Average True Range (ATR)
- SFWL 0.04
- TNXP 2.56
- MACD
- SFWL 0.00
- TNXP -0.84
- Stochastic Oscillator
- SFWL 30.70
- TNXP 0.82
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. The company offers contract logistics services comprising planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services. The integrated logistics solution services of the company are comprised of three segments: B2B freight transportation; cloud storage; and value-added services.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.